rrna synthesis

4-Thiouridine (4-SU) is a photoactivatable ribonucleoside analog that is widely used for RNA analysis, including short-range RNA-RNA crosslinking and nascent RNA labeling. The crosslinking thio moiety is attached directly to the nucleotide base, thus 4-SU

Erythromycin (E-Mycin) is a Macrolide and Macrolide Antimicrobial. The physiologic effect of erythromycin is by means of Decreased Sebaceous Gland Activity.

Clindamycin hydrochloride monohydrate (Clindamycin alcoholate) is a protein synthesis inhibitor used orally, capable of diminishing virulence factor expression in Staphylococcus aureus at sub-minimum inhibitory concentrations (sub-MICs). It acts by suppressing Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1), and alpha-haemolysin (Hla) production. Resistance to this compound emerges through enzymatic methylation at the antibiotic's 50S ribosomal subunit binding site (23S rRNA).

Amikacin disulfate (BAY-416651 sulfate) is a semi-synthetic aminoglycoside antibiotic derived from kanamycin A.

CX5461 is an rRNA synthesis inhibitor with oral activity that inhibits Pol I-driven rRNA transcription. CX5461 activates the DNA damage response and has antitumor activity in tumors such as ovarian cancer.

7-Methylguanosine 5'-diphosphate (7-Methyl-GDP) sodium, a cap analog, is utilized in the synthesis of mRNA cap analogues[1].

NusB-IN-1 (Compound 22r) is a highly effective, orally administered bacterial rRNA synthesis inhibitor with potent antimicrobial activity against MRSA and VRSA [1].

CX-5461 dihydrochloride is a potent, orally active inhibitor of Pol I-mediated rRNA synthesis that acts on HCT-116 cells (IC50: 142 nM), A375 cells (IC50: 113 nM) and MIA PaCa-2 cells (IC50: 54 nM), and to a lesser extent on Pol II (IC50 ≥ 25 μM).

Pidnarulex HCl is the salt form of CX-5461, a first-in-class non-genotoxic small molecule targeted inhibitor of RNA polymerase I (Pol I) that activates the p53 pathway without causing DNA damage. CX-5461 selectively inhibits rRNA synthesis by Pol I in the nucleolus, but does not inhibit mRNA synthesis by RNA Polymerase II (Pol II) and does not inhibit DNA replication or protein synthesis. Inhibition of Pol I results in nucleolar stress and release of ribosomal proteins (RP) from the nucleolus. The RP bind to Mdm2 and liberate p53 to orchestrate apoptosis in cancer cells. CX-5461 demonstrates a favorable preclinical profile, potently and selectively kills cancer cells, demonstrates robust in vivo efficacy in multiple models, and has demonstrated oral bioavailability in multiple species.

Clindamycin hydrochloride monohydrate (Standard) is the standard substance of Clindamycin hydrochloride monohydrate, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Clindamycin hydrochloride monohydrate (Clindamycin alcoholate) is a protein synthesis inhibitor used orally, capable of diminishing virulence factor expression in Staphylococcus aureus at sub-minimum inhibitory concentrations (sub-MICs). It acts by suppressing Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1), and alpha-haemolysin (Hla) production. Resistance to this compound emerges through enzymatic methylation at the antibiotic's 50S ribosomal subunit binding site (23S rRNA).